News and Conferences

Transpharmation's Scientific Lead for EEG, Sleep and Epilepsy, Sandor Kantor PhD, will be making a spotlight presentation on the 24th of November at 13.20-13.50. His presentation is titled 'The effect of CNS-acting drugs on rodent mismatch negativity is modulated by vigilance states' and will expand on the following aspects: Mismatch negativity (MMN) is a component of event-related potentials that is diminished in many neuropsychiatric disorders including schizophrenia; Central nervous system (CNS)-acting drugs often alter vigilance states, and it is not well understood how the drug-induced changes in sleep-wake behaviour affect MMN generation; An overview of the recent rodent MMN research with a special focus on vigilance state specific changes and discuss the methodological aspects and future implications of the latest findings.

For further information about this event please see here:

https://www.hub-xchange.com/cns-therapeutics-xchange-europe-2022/#anchor1 

To view the presentation after the event please contact us. 

This year’s prestigious event is taking place at the San Diego Convention Centre in San Diego, CA. We are looking forward to seeing familiar faces and meeting new ones. Covering a number of our translational services, we will have several posters on display, along with several members of our scientific team on hand to answer questions, hold meetings and update you on the latest developments that we are able to offer you. Keep an eye on our Linkedin profile for more details coming out soon.

The annual ECNP Congress is Europe’s premier scientific meeting for disease-oriented brain research, annually attracting more than 5,000 psychiatrists, neuroscientists, neurologists and psychologists from around the world. Transpharmation will be presenting two posters; (1) Differential effects of repeated treatment with DOI and psilocybin on the head-twitch response (HTR), locomotor activity and anxiety-like behaviour and (2) 2,5-Dimethoxy-4-iodoamphetamine (DOI) enhances motivation in low and medium but not high performers in the progressive ratio (PR) task in rats. We look forward to seeing you, but if you are unable to attend this event, we will make the posters available to you on our publications page after October 18th. For more details, please feel free to contact us.

With preclinical/clinical transition being the largest failure risk in CNS therapeutics development, Transpharmation will be revealing new scientific development work at the 2022 HubXchange’s CNS Therapeutics West Coast round table meeting, where senior drug developers from pharma and biotech share experiences and discuss the future research landscape. Chief Scientific Officer Guy Higgins, PhD, is a keynote speaker this year and will be presenting 'An application of a versatile rodent operant platform to drug discovery today.'

We will make this work available on our website if you are unable to attend. 

Read about hubXchange.

This event will focus on neurobiology within the areas of psychiatry and psychology, behaviour, addiction models and neurodegenerative diseases. Transpharmation will be on hand to present a recent study; "Stress based animal models: refinement vs. translation". If you are not attending this conference, our work will be made available for you to see in our Publications page after the event.

The Safety Pharmacology Society (SPS) presents its Annual Meeting in partnership with the Canadian Society of Pharmacology and Therapeutics (CSPT). There's lots going on; find out more here https://web.cvent.com/event/7f5258b7-2dac-4efb-b6ff-6789cff237fe/summary. We will be at Booth 310 where we look forward to talking to you about our PK and safety pharmacology capabilities in rodents and dogs, and to discuss your study needs. See you there!